Can Magnetic Seizure Therapy Compete With ECT? Reading CREST-MST Carefully
Why the Comparison with ECT Is Clinically Loaded
Electroconvulsive therapy occupies a strange place in modern psychiatry. It is among the most effective treatments for severe depression, especially when symptoms are dangerous, psychotic, treatment-resistant, or associated with urgent suicidal risk. At the same time, it remains one of the most feared interventions in mental health care. Some of that fear is historical and cultural. Some is grounded in real clinical concerns, especially memory problems, post-treatment confusion, anesthesia, and the burden of repeated procedures. Magnetic seizure therapy enters this landscape as a related but distinct intervention. Like ECT, it is a convulsive therapy: the treatment intentionally induces a therapeutic seizure under anesthesia. Unlike ECT, it uses magnetic stimulation rather than direct electrical stimulation. The hope is that MST can preserve much of the antidepressant benefit of seizure therapy while reducing cognitive adverse effects, particularly autobiographical memory disruption.
That makes the CREST-MST trial clinically important, but also easy to overstate. The question is not whether MST has “defeated” ECT. The more precise question is whether it can come close enough to a modern ECT protocol on antidepressant outcomes while offering a better cognitive safety profile. In interventional psychiatry, a treatment’s value is rarely determined by efficacy alone. It also depends on what patients must tolerate to reach remission.
What CREST-MST Actually Tested
CREST-MST was a randomized, double-blind, non-inferiority trial comparing magnetic seizure therapy with right unilateral ultra-brief pulse-width electroconvulsive therapy in depression. The comparator matters. Right unilateral ultra-brief ECT is not the older, most cognitively burdensome version of ECT that many patients imagine. It is a contemporary technique designed to reduce cognitive adverse effects while retaining clinical efficacy. This makes the trial more demanding. If MST had been compared with a more cognitively aggressive ECT protocol, a cognitive advantage would have been easier to show. Comparing it with right unilateral ultra-brief ECT sets a higher bar: MST must compete with a version of ECT already optimized, at least partly, for tolerability.
MST itself sits in an unusual position between familiar categories. It is not standard repetitive TMS, which is nonconvulsive and typically delivered without anesthesia. It is also not simply ECT with a different device. MST uses high-intensity magnetic pulses to induce a seizure. Because magnetic fields can pass through the skull without the same electrical impedance as direct electrical stimulation, the intervention is designed to be more focal. In theory, that could reduce spread to brain regions involved in memory, especially medial temporal structures.
The trial’s clinical question therefore combines two aims: antidepressant efficacy and cognitive safety. The depression outcome asks whether MST can achieve remission at a rate close enough to ECT. The tolerability outcome asks whether patients experience less cognitive harm. This dual focus is the reason CREST-MST is relevant beyond a narrow procedural debate. It tests whether convulsive therapy can be redesigned around patient acceptability, not only symptom reduction.
Why Non-Inferiority Logic Matters
A non-inferiority trial is often misunderstood. It is not designed to prove that a new treatment is better than the standard treatment. It asks whether the new treatment is not worse by more than a prespecified margin. That margin is crucial. A treatment can be statistically non-inferior and still have numerically lower efficacy. The clinical acceptability of that tradeoff depends on what the new treatment offers in return. This logic fits MST well. ECT already has a strong efficacy record, so a placebo-controlled design would not answer the most relevant clinical question. Patients and clinicians are not usually choosing between ECT and nothing. They are choosing between established ECT and possible alternatives that may be less frightening, less cognitively disruptive, or more acceptable.
In CREST-MST, the relevant question is whether MST can produce remission rates close enough to right unilateral ultra-brief ECT while improving cognitive outcomes. If it can, then a slightly different efficacy profile may still be clinically meaningful. The point is not mathematical equivalence. The point is whether the total clinical package is competitive. This is where headlines can become misleading. “Non-inferior” does not mean identical. It does not mean MST can replace every form of ECT for every patient. It does not establish superiority. It also depends on the chosen non-inferiority margin, trial population, adherence, missing-data handling, outcome definitions, and the quality of the comparator.
CREST-MST reported that MST was non-inferior to right unilateral ultra-brief ECT in achieving remission of depression and had a more favorable cognitive safety profile. That is a serious result. It supports MST as a plausible alternative within convulsive therapy research. But the conclusion remains anchored to the conditions of the trial: this specific MST protocol, this specific ECT comparator, and this studied population.
The trial also changes the framing of innovation. In severe depression, a new treatment does not always need to beat the gold standard on symptom outcomes to matter. If it approaches the efficacy of a powerful intervention while reducing one of its major liabilities, it can still alter clinical decision-making.
Efficacy Versus Tolerability: What The Trial Adds
For many patients, the biggest barrier to ECT is not the abstract idea of seizure induction. It is the fear of memory loss. Even when clinicians explain that modern ECT can be delivered in ways that reduce cognitive risk, patient concerns remain understandable. Memory is not a minor side effect. It shapes identity, independence, work, relationships, and trust in treatment.
MST is interesting because it targets this barrier directly. Its promise is not convenience. It still requires anesthesia, seizure monitoring, trained staff, specialized equipment, and repeated treatment sessions. From a patient’s perspective, it remains an intensive intervention. The potential advantage is cognitive tolerability: a way to use seizure therapy with less disruption to memory. The CREST-MST findings therefore contribute to a broader debate in psychiatry: how much efficacy is enough if tolerability improves? In depression care, this question appears repeatedly. A medication may be effective but poorly tolerated. A device treatment may work but be inaccessible. A psychotherapy may be evidence-based but emotionally difficult. A rapid treatment may help acutely but raise durability questions. No intervention is judged by symptom change alone.
ECT’s strength is its depth of evidence and clinical experience. It has a long record in severe depression, psychotic depression, catatonia, and acute high-risk presentations. It can be lifesaving. MST does not yet have that breadth of evidence. It remains newer, less available, and more dependent on further implementation work.
Still, a cognitive safety advantage would not be a marginal issue. It could affect willingness to start treatment, willingness to continue, family acceptance, clinician recommendation, and institutional adoption. If a patient refuses ECT because of memory concerns, then a somewhat more acceptable convulsive therapy could expand access to an effective treatment category rather than merely compete within it. This is also where right unilateral ultra-brief ECT as comparator becomes important. The trial did not set up an easy contrast between “bad old ECT” and “new gentle MST.” It compared MST with a modern ECT strategy already designed to limit cognitive harm. A favorable cognitive profile in that context is more persuasive than it would be against a less refined comparator.
The result also invites a more patient-centered definition of success. Remission remains the primary goal. A treatment that does not relieve depression cannot be justified by tolerability alone. But when two interventions approach similar antidepressant territory, the cognitive and experiential burden becomes central. In severe depression, success means not only getting patients better, but doing so in a way they can accept and recover from.
What CREST-MST Does and Does Not Settle
CREST-MST strengthens the case for magnetic seizure therapy as a serious candidate in interventional psychiatry. It suggests that MST can compete with a modern ECT protocol on remission while offering a more favorable cognitive safety profile. For patients who might otherwise avoid ECT because of memory concerns, that possibility is clinically meaningful.
However, the trial does not dethrone ECT. It does not prove that MST is superior to ECT. It does not show equivalence to all ECT techniques, all severity groups, or all emergency contexts. It also does not resolve questions of long-term relapse prevention, maintenance treatment, cost-effectiveness, device availability, training, regulatory approval, or real-world feasibility. Those questions matter because MST is not a low-burden outpatient wellness intervention. It belongs to the convulsive therapy family. It requires anesthesia and seizure induction. It would need the same seriousness of screening, monitoring, consent, and post-treatment care that surrounds ECT. A better cognitive profile would make it more acceptable, not casual.
The useful conclusion is therefore measured. CREST-MST narrows the gap between an established but feared treatment and a newer intervention designed to reduce one of ECT’s major liabilities. It does not turn MST into a universal replacement. It makes MST harder to dismiss.
The broader lesson extends beyond MST itself. Psychiatry often asks whether a treatment works. CREST-MST pushes a more practical question: does it work well enough, with fewer costs that patients find unacceptable? For severe depression, that may be the right standard. If future studies confirm the findings and implementation becomes feasible, MST could become an important option for patients who need the power of convulsive therapy but fear the cognitive burden of ECT.
References
- Blumberger, D. M., Daskalakis, Z. J., Tamminga, C., Throop, A., et al. (2026). Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST–MST): A randomised, double-blind, non-inferiority trial in Canada and the USA. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(26)00060-X